By proceeding, you agree to our Terms of Use and Privacy Policy.
Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.
21-22 August 2023
The 8th annual Liquid Biopsy for Disease Management: From Discovery to Clinical Use conference will review new liquid biopsies coming on the market that have increased sensitivity and are robust enough for clinical applications for measuring treatmen
Event Ended
Hybrid
Paid
Washington, DC
The point-of-care industry is poised for tremendous growth and is fueled by both the explosion of enabling technologies as well as the huge need for disruption in the medical sector as consumers demand flexibility and access to testing as well as fas
Development of companion diagnostics shows no signs of slowing down anytime soon. As the field continues to grow, it is critical that the surrounding landscape progresses with it. Partnerships between pharmaceutical and diagnostic companies can lead
22-23 August 2023
The increase in testing and demands of the COVID-19 pandemic has spurred tremendous innovation for infectious disease testing platforms that reduce time, cost, and offer greater access than ever before. At the 15th Annual Advanced Diagnostics for Inf
As diagnostics become increasingly complex, coverage and reimbursement come to the forefront of challenges that diagnostic companies face. Deep understanding of how policy is developed and implemented and how policy will change over time will provide
Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that there are no screening tests available for the majority of cancers, and far too often cancer is only detected onc
Within the last few years, we saw a seismic global shift in the acceptance and availability of point-of-care and home-based testing, bolstered by a heightened interest in and capability for decentralized processes. Healthcare systems and providers we